Allergan Divests Brazikumab and Zenpep to Move Forward with AbbVie Acquisition
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 1 (Table of Contents)
Published: 31 Jan-2020
DOI: 10.3833/pdr.v2020.i1.2508 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a move to satisfy regulators, Allergan has agreed to return the rights to inflammatory bowel disease therapy brazikumab to AstraZeneca and divest its gastrointestinal treatment Zenpep® (pancrelipase) to Nestle...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS